淋巴管内碘对比剂暴露新生儿原发性甲状腺功能减退的早期识别:病例系列
该病例系列报告4例早产儿在淋巴管内碘对比剂暴露后发生原发性甲状腺功能减退,其中2例TSH显著升高至335.7和470.2 mIU/mL,另2例TSH轻度升高伴尿碘明显增高,所有患者经左甲状腺素治疗后甲状腺功能改善。提示淋巴管内碘暴露是医源性原发性甲减的重要风险因素,暴露后需密切监测甲状腺功能。
要点
- 淋巴管内碘对比剂暴露后早产儿可发生严重原发性甲减,TSH可显著升高。
- 暴露后短期内即可出现TSH升高,需尽早监测甲状腺功能。
- 左甲状腺素治疗可改善甲状腺功能,避免长期不良结局。
核心结论
- 淋巴管内碘对比剂应被视为医源性原发性甲状腺功能减退的重要风险因素,尤其在早产儿暴露后短期内。
- 密切监测甲状腺功能对避免该人群潜在长期不良结局至关重要。
研究设计与样本
- 病例系列,报告4例既往甲状腺功能正常的早产儿在淋巴管内碘对比剂暴露后发生甲状腺功能减退。
主要发现
- 患者1和2分别在出生后第97天和第43天行淋巴管造影,后于第111天和第68天出现严重原发性甲减,TSH分别为335.7 mIU/mL和470.2 mIU/mL(参考范围1.7-9.1)。
- 患者3于出生后第90天行淋巴管造影,4天后TSH为13.35 mIU/mL(参考范围1.7-9.1),尿碘为1742 µg/L(正常<200)。
- 患者4于出生后第4天经淋巴管暴露碘,3天后TSH为16.7 µU/mL(参考范围1.7-9.1),尿碘为228,712 µg/L(正常<200)。
- 所有患者接受左甲状腺素治疗后甲状腺功能检查结果改善。
临床怎么用
- 对接受淋巴管内碘对比剂的早产儿,应尽早并密切监测甲状腺功能,以及时发现医源性原发性甲减。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: In neonates, iatrogenic hypothyroidism can result from topical or IV iodine exposure. Data on intralymphatic iodine exposure, risk factors for disease severity, and timing of hypothyroidism are limited. CASE DESCRIPTIONS: We report 4 cases of premature neonates with previously normal thyroid function tests (TFTs) who developed hypothyroidism after intralymphatic iodinated contrast. Patients 1 and 2, premature infants with complex medical histories, had chylous effusions and high-volume chest tube output requiring imaging with lymphangiograms on day of life (DOL) 97 and DOL 43, respectively. They developed severe, primary hypothyroidism with TSH of 335.7 mIU/mL (reference range, 1.7 to 9.1) on DOL 111 and TSH of 470.2 mIU/mL (reference range, 1.7 to 9.1) on DOL 68. Patient 3 had prenatally diagnosed fetal hydrops manifesting with chylous effusions and high-volume chest tube output. The infant underwent lymphangiography on DOL 90 and was noted to have an elevated TSH of 13.35 mIU/mL (reference range, 1.7 to 9.1) 4 days later with spot urine iodine of 1742 µg/L (normal, <200). Patient 4 had a lymphatic malformation and underwent sclerotherapy with doxycycline with intralymphatic iodine exposure on DOL 4 and was found to have a TSH of 16.7 µU/mL (reference range, 1.7 to 9.1) 3 days later with spot urine iodine of 228,712 µg/L (normal, <200). The TFT results for all patients improved after levothyroxine administration. CONCLUSION: Intralymphatic iodine should be considered a major risk factor in the development of iatrogenic primary hypothyroidism, especially in premature neonates soon after exposure. Close monitoring of TFTs is imperative to avoid potential long-term adverse outcomes in this population.
引用
- Cherella CE, Breault DT, Thaker V, et al. Early Identification of Primary Hypothyroidism in Neonates Exposed to Intralymphatic Iodinated Contrast: A Case Series. J Clin Endocrinol Metab. 2018. PMID: 30085021. doi:10.1210/jc.2018-00960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。